Request Demo
Last update 13 Jan 2025
Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)
Last update 13 Jan 2025
Overview
Basic Info
Drug Type TIL therapy |
Synonyms GC101 TIL |
Target- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
11
Clinical Trials associated with Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)CTR20244769
自体天然肿瘤浸润淋巴细胞注射液（GC101 TIL）对比研究者选择的化疗治疗晚期黑色素瘤患者的开放标签、随机、对照、多中心 II 期临床研究（MIZAR-003）
[Translation] An open-label, randomized, controlled, multicenter phase II clinical study of autologous natural tumor-infiltrating lymphocyte injection (GC101 TIL) versus investigator's choice of chemotherapy in patients with advanced melanoma (MIZAR-003)
NCT06703398
A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma
NCT06473961
An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung Cancer
100 Clinical Results associated with Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)
Login to view more data
100 Translational Medicine associated with Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)
Login to view more data
100 Patents (Medical) associated with Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)
Login to view more data
100 Deals associated with Autologous Natural Tumor Infiltrating Lymphocytes(Shanghai Gencells Therapeutics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Uveal Melanoma | Phase 2 | CN | 20 Dec 2024 | |
| Metastatic melanoma | Phase 2 | CN | 08 Nov 2023 | |
| metastatic non-small cell lung cancer | Phase 1 | CN | 14 Oct 2024 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 24 Sep 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 12 Oct 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free